CTRI/2020/09/028070进行中（未招募）3 期
A prospective, multicenter, randomized, double blind, Phase III study to compare the efficacy and safety of Biosimilar Adalimumab injection of Enzene Biosciences Ltd. with HUMIRA�® (adalimumab) injection in subjects with active Ankylosing spondylitis (AS).
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or Female subjects between 18 to 65 years of age
- •2. Subjects with diagnosis of Axial Ankylosing spondylitis based on the 1984 modified New York classification criteria, has active AS, as defined by fulfillment of at least 2 of the following 3 conditions at both Screening and Baseline visits:
- •a. BASDAI score ââ?°Â¥ 4
- •b. Total back pain on a visual analog scale ââ?°Â¥ 4
- •c. Morning stiffness ââ?°Â¥ 1 hour
- •4. Has inadequate response to or intolerance to one or more non-steroidal anti-inflammatory drugs (NSAIDs) as assessed by the Investigator
- •5. Willing and able to comply with the protocol. Willing and able to comply with the protocol.
排除标准
- •1. Has total spinal ankylosis
- •2. Has undergone spinal surgery or joint surgery involving joints assessed within 2 months prior to screening
- •3. Has received intra-articular joint injection(s), spinal or paraspinal corticosteroid injection(s) within 28 days prior to Baseline
- •4. Has prior exposure to any anti-TNF therapy at any time
- •5. Subjects with clinically active TB
- •6. Subjects with underlying conditions that may predispose them to infection
- •7. Subjects with history or presence of cardiac, renal, neurologic, psychiatric, endocrinologic, metabolic, or hepatic disease which in the opinion of the investigator does not allow participation of the subject in this study
- •8. Known hypersensitivity to any component of the investigational product and other medications used in this study
- •9. Subjects with a non-healed fracture
- •10. Subjectââ?¬•s having the following laboratory results at screening
- •a. Absolute neutrophil count (ANC) < 1,500/mm3 b. Hemoglobin (Hb) <10 g/dL
- •c. Platelet count < 100,000/mm3
- •d. Total bilirubin level > 1.5 times the upper limit of the normal laboratory range (ULN)
- •e. AST and ALT >3 x ULN
- •f. Alkaline phosphatase >3 x ULN
- •g. Serum Creatinine level > 1.25 xULN
- •11. Subjects suffering from acute or chronic infection(s)
- •12. Subjects with congestive heart failure
- •13. Positive serology for human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) at screening
- •14. Subjects of child bearing potential, who are not willing to use adequate contraception during the study period.
- •15. Female subjects who are pregnant or nursing
- •16. Has any concurrent disease or condition, which in the opinion of the investigator does not allow participation of the subject in this study
- •17. Has participated in any other clinical trial and received experimental medications within 4 weeks prior to screening
研究者
相似试验
进行中（未招募）
1 期
A comparison study to look at the safety and effectiveness of a new drug (masitinib) for treating a prostrate cancer which can spread and which is not easily to be removed against a currently used treatment (docetaxel & prednisone).Castrate Resistant Prostate Cancer (mCRPC)MedDRA version: 21.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000809-23-GBAB Science580
Unknown
3 期
A phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancerCTRI/2015/10/006331AB Science2
进行中（未招募）
1 期
Study to evaluate 2 types of treatment (masitinib + FOLFIRI or placebo + FOLFIRI) in the treatment of patients with metastatic colorectal cancer that have received 1 previous therapyEUCTR2013-000490-79-CZAB Science574
进行中（未招募）
1 期
Study to evaluate 2 types of treatment as first line treatment (masitinib + docetaxel or placebo + docetaxel ) in the treatment of patients with metastatic Castrate Resistant Prostate Cancer (mCRPC)EUCTR2013-000809-23-SKAB Science581
进行中（未招募）
1 期
Study to evaluate 2 types of treatment (masitinib + FOLFIRI or placebo + FOLFIRI) in the treatment of patients with metastatic colorectal cancer that have received 1 previous therapyEUCTR2013-000490-79-GRAB Science574